Research Article
Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies
đź“– doi.org/10.3899/jrhe...
@harvardmed.bsky.social @stanford.edu
@jrheumatol.bsky.social
@jrheumatol.bsky.socialResearch Article
Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies
đź“– doi.org/10.3899/jrhe...
@harvardmed.bsky.social @stanford.edu
@dermatologyadvisor.bsky.socialBrepocitinib in patients with #dermatomyositis was associated with improvements in cutaneous disease activity, #pruritus, and skin-related quality of life through 52 weeks.